DBV Technologies (NASDAQ:DBVT – Get Free Report)‘s stock had its “market outperform” rating reiterated by equities researchers at JMP Securities in a report released on Friday,Benzinga reports. They currently have a $10.00 target price on the stock. JMP Securities’ target price would suggest a potential upside of 141.55% from the company’s previous close.
Several other research analysts have also issued reports on the stock. HC Wainwright increased their price target on shares of DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, October 24th. StockNews.com started coverage on shares of DBV Technologies in a report on Thursday. They set a “hold” rating for the company.
Check Out Our Latest Report on DBVT
DBV Technologies Price Performance
DBV Technologies Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.
Read More
- Five stocks we like better than DBV Technologies
- How to Most Effectively Use the MarketBeat Earnings Screener
- 3 EV Stocks Offering Unique Alternatives to Tesla
- How to Choose Top Rated Stocks
- 3 Stocks Leveraging NVIDIA’s Strength for Profits
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Walgreens Stock Poised for a Rebound: Why Analysts Are Bullish
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.